<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Caspian J Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">Caspian J Intern Med</journal-id><journal-id journal-id-type="publisher-id">CJIM</journal-id><journal-title-group><journal-title>Caspian Journal of Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">2008-6164</issn><issn pub-type="epub">2008-6172</issn><publisher><publisher-name>Babol University of Medical Sciences</publisher-name><publisher-loc>Babol, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28702150</article-id><article-id pub-id-type="pmc">5494045</article-id><article-id pub-id-type="doi">10.22088/cjim.8.2.108</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Adding ofloxacin to standard triple-drug regimens increased the Helicobacter pylori eradication rate: Data from randomized clinical trial </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sadeghi-Hadad-Zavareh</surname><given-names>Mahmoud</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Seyyedsaeid</given-names></name><degrees>MD</degrees><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hajiahmadi</surname><given-names>Mahmoud</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Javanian</surname><given-names>Mostafa</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Habibian</surname><given-names>Masoomeh</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</aff><aff id="aff2"><label>2</label>Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</aff><aff id="aff3"><label>3</label>Non-Communicable Pediatric Diseases Research Center, Babol University of Medical Sciences, Babol, Iran.</aff><aff id="aff4"><label>4</label>Student Research Committee, Babol University of Medical Sciences, Babol, Iran.</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence: &#x000ac;&#x000ac;Seyyedsaeid Mohammadi, Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran ,Email: ssmmbb293@yahoo.com, Tel: 0098 1132238284, Fax: 0098 1132238284</corresp></author-notes><pub-date pub-type="ppub"><season>Spring</season><year>2017</year></pub-date><volume>8</volume><issue>2</issue><fpage>108</fpage><lpage>111</lpage><history><date date-type="received"><day>7</day><month>6</month><year>2015</year></date><date date-type="rev-recd"><day>10</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2016</year></date></history><permissions><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>The rate of Helicobacter pylori (H.pylori) eradication in dyspeptic patients using bismuth- based triple therapy is low due to bacterial that are resistant to antibiotics. The results of recent studies regarding levofloxacin have been encouraging, but the high cost of treatment prevents its routine administration. We, therefore, performed the present double-blind clinical trial to compare the efficiency of quadruple-drug regimen containing ofloxacin, clarithromycin, amoxicillin, and omeprazole and the same standard triple-therapy regimen minus ofloxacin in H. pylori positive dyspepsia.</p></sec><sec><title>Methods:</title><p>The study patients were recruited among dyspeptic patients requiring gastroscopy. Patients with the history of H.pylori treatment, renal failure and pregnancy were excluded. Diagnosis of H.pylori infection was confirmed by rapid urease test and response to treatment was confirmed via negative urease breath test (UBT) 20 days after completion of treatment. Patients were allocated intermittently to standard triple therapy containing amoxicillin, clarithromycin, omeprazole alone or plus ofloxacin for ten days. Response to treatment was compared between the two groups.</p></sec><sec><title>Results:</title><p> A total of 140 patients entered the study (70 patients in each group). At endpoint 30 (42.9%) patients of group 1 and 39 (55.7%) patients of group 2 became asymptomatic. Furthermore, 55 (78.6%) patients of group 1 and 66 (94.3%) patients of group 2 revealed negative urea breath test (P= 0.01).</p></sec><sec><title>Conclusion:</title><p>This study indicates adding ofloxacin to standard triple-therapy for H.pylorri infection significantly increases the rate of eradication. These findings highlight ofloxacin as empiric treatment of H. pylori infection.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Helicobacter pylori</kwd><kwd>Dyspepsia</kwd><kwd>Triple therapy</kwd><kwd>Ofloxacin</kwd></kwd-group></article-meta></front><body><p>Helicobacter pylori (H. pylori) eradication is recommended in many conditions including peptic ulcer disease, MALToma, and gastric cancer (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B5" ref-type="bibr">5</xref>). Empirical regimens are expected to eradicate HP infection in more than 90% of patients. Research in Iran and other Asian countries showed that about 50% of the H.pylori infection are resistant to metronidazole (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>) and 17% to clarithromycin. The inefficiency of bismuth-based therapy for H.pylori has been shown (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>) and so many researchers recommend quadruple-therapy using levofloxacin as their first line treatment (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). However, because of high cost, ofloxacin is used instead of levofloxacin for H.pylori eradication in Iran. Nonetheless, the data regarding the efficiency of ofloxacin in H.pylori infection are scarce. Thus, the present study was conducted to determine the eradication rate of H.pylroi infection with quadruple regimen containing clarithromycin, amoxicillin, ofloxacin and omeprazole.</p><sec sec-type="methods"><title>Methods</title><p>This double- blind, randomized clinical trial was performed in Ayatollah Rouhani Hospital during 2014 to 2015 (IRCT2015113025292N1). The study patients were those required to have diagnostic upper endoscopy for dyspepsia. Exclusion criteria were history of previous treatment for H.pylori, presence of renal failure and pregnancy (<xref ref-type="fig" rid="F1">fig 1</xref>). This study was approved by the Ethics Committee of Babol University of Medical Sciences. Informed consent was taken from all the study participants. All patients underwent endoscopy performed by a single gastroenterologist and the presence of H.pylori infection was confirmed with rapid urease test (RuT) using Heliprobe kit (Kibion, Uppsala, Sweden).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>The exclusion flow chart of studied patient</p></caption><graphic xlink:href="cjim-8-108-g001"/></fig><p>Drug regimens were similar and all participants provided at least one regular prescription medication. Patients were alternately allocated to receive either group A regimen containing amoxicillin (500 mg orally twice daily for 10 days, Farabi co. Iran), clarithromycin (500 mg, orally twice daily for 10 days, Farabi co, Iran), omeprazole (20 mg orally twice daily for 10 days, Abidi co, Iran) or group B with same standard regimen plus ofloxacin (200 mg orally twice daily for 5 days, Exir co, Iran). Response to treatment was considered as negative UBT which was performed 20 days after completion of treatment. In addition, the two groups were compared with regard to the frequency of gastrointestinal symptoms. Data collection regarding treatment response was provided by the gastroenterologist who was blind to treatment regimen. Statistical analysis was also performed by a blind analyzer. SPSS Version 20 and chi-square test were used for statistical analysis.</p></sec><sec sec-type="results"><title>Results</title><p>A total of 140 patients (70 participants for each group) entered the study. The baseline characteristics of the study population in both treatment groups are presented in <xref ref-type="table" rid="T1">table 1.</xref> Over the study period, 13 patients lost to follow-up and 3 patients did not complete treatment. At endpoint, 55 (78.6%) patients taking regimen A and 66 (94.3%) patients taking regimen B responded to treatment (P=0.01). Furthermore, at the end of the study period 30 (42.9%) patients of group A and 39 (55.7%) patients of group B became asymptomatic. <xref ref-type="table" rid="T1">Table 1</xref> shows the baseline characteristics of all individuals enrolled.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Basic characteristic of studied patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#0000FF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Variables</bold>
</th><th style="background-color:#0000FF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Control</bold>
<break/>
<bold>N (%)</bold>
</th><th style="background-color:#0000FF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Case</bold>
<break/>
<bold>N (%)</bold>
</th><th style="background-color:#0000FF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr></thead><tbody><tr><td style="background-color:#B8CCE4;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#B8CCE4;" align="left" valign="middle" rowspan="1" colspan="1">Male<break/>Female</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">28(40)<break/>42(60)</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">37(52.9)<break/>33(47.1)</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">0.175</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Age group</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Less than 40 years<break/>More than 40 years</td><td align="center" valign="middle" rowspan="1" colspan="1">23(32.9)<break/>47(67.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">35(50)<break/>35(50)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.115</td></tr><tr><td style="background-color:#B8CCE4;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Level of Education</bold>
</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#B8CCE4;" align="left" valign="middle" rowspan="1" colspan="1">Below high school<break/>Diploma <break/>Bachelor diploma and higher</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">9(12.9)<break/>49(70)<break/>12(17.1)</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">14(20)<break/>45(64.3)<break/>11(15.7)</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">0.245</td></tr></tbody></table></table-wrap><p>After completion of treatment, 30 (42.9%) patients of group A and 39 (55.7%) patients of group B did not have any symptoms. 55 (78.6%) cases in group A and 66 (94.3%) cases in group B had negative UBT. Based on the comparison between two groups of drug regimen and the eradication rate of infection, there is a significant relation (P=0.01) (<xref ref-type="table" rid="T2">table 2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Univariate analysis of the clinical factors influencing the efficacy of H.pylori eradication</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#0000FF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Characteristics</bold>
</th><th style="background-color:#0000FF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Eradication rate (%)</bold>
</th><th style="background-color:#0000FF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>P- value</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;40<break/>&#x02265;40</td><td align="center" valign="middle" rowspan="1" colspan="1">89.7<break/>84.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45</td></tr><tr><td style="background-color:#B8CCE4;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#B8CCE4;" align="left" valign="middle" rowspan="1" colspan="1">Male<break/>Female</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">89.2<break/>84</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Residency</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Urban<break/>Rural</td><td align="center" valign="middle" rowspan="1" colspan="1">84.1<break/>81.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46</td></tr><tr><td style="background-color:#B8CCE4;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Regimen</bold>
</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#B8CCE4;" align="left" valign="middle" rowspan="1" colspan="1">A<xref ref-type="table-fn" rid="TFN1">*</xref><break/>B<xref ref-type="table-fn" rid="TFN2">**</xref></td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">78.6<break/>94.3</td><td style="background-color:#B8CCE4;" align="center" valign="middle" rowspan="1" colspan="1">0.01</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p> Amoxicillin, Clarithromycin, omeprazole </p></fn><fn id="TFN2"><label>**</label><p> A+ Ofloxacin </p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p> The findings of this study revealed significantly the higher rate of H.pylori eradication at 93.5% in drug regimen containing ofloxacin. Regarding patients&#x02019; selection and study design, greater efficiency of quadruple therapy should be attributed to ofloxacin. Empirical therapy for H.pylori infection should be effective in more than 90% of patients, whereas in Iran, the efficacy of standard therapy is about 80% (<xref rid="B10" ref-type="bibr">10</xref>) which may be attributed to drug resistance, particularly bismuth or metronidazole (<xref rid="B11" ref-type="bibr">11</xref>). As observed in the present study, standard therapy was effective only in 78.6% of the treated patients. These results suggest to include ofloxacin in empirical treatment, in particular since ofloxacin compared with leveofloxacine is cheaper in price and makes it the preferred choice in empiric therapy.</p><p>This effect of treatment was not related to age, gender and location. In a study by Sierra et al., successful eradication of triple therapy was less than 80%. In the current study, H.pylori eradication triple therapy rate was 78.57% which was comparable to our study. The authors found no additional efficacy by including bismuth to triple therapy and recommended the levofloxacin triple therapy as the first-line therapy for H.pylori eradication (<xref rid="B12" ref-type="bibr">12</xref>). Irardi et al. found greater efficiency with triple therapy based on amoxicillin, clarithromycin and rabeprazole (<xref rid="B7" ref-type="bibr">7</xref>). In a study, H.pylori eradication rate was below 90%, which was consistent with the results reported by Federico et al. The authors recommended the use of floroquinolones as the first-line therapy for H.pylori eradication (<xref rid="B6" ref-type="bibr">6</xref>).</p><p> In another study conducted by Onyekwere et al., the eradication rate of triple therapy including amoxicillin, clarithromycin and omeprazole was compared according to duration treatment period. In this study, the results of 7-day and 14-day treatment were comparable (<xref rid="B13" ref-type="bibr">13</xref>). </p><p>In conclusion, the results of this study indicate that adding ofloxacin to triple-therapy regimen increases the rate of H.pyloryi eradication and highlights the quadruple regimen as the first line empiric therapy in dyspeptic patients. Due to its lower cost, easy accessibility and higher rate of treatment response, ofloxacin should be considered as the H.pylori infection treatment in Iran.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the Clinical Research Development Unit of Ayatollah Rouhani Hospital.</p></ack><sec><title>Funding:</title><p>This paper has been extracted from Masoomeh Habibian&#x02019;s thesis with registration number 445 Which was financially supported by Babol University of Medical Sciences with grant number 2306, Iran. </p></sec><sec sec-type="COI-statement"><title>Conflict of interest</title><p>There was no conflict of interest.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>BJ</given-names></name><name><surname>Warren</surname><given-names>JR</given-names></name></person-group><article-title>Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration</article-title><source> Lancet</source><year>1984</year><volume>1</volume><fpage>1311</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">6145023</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>JJ</given-names></name><name><surname>Chung</surname><given-names>SC</given-names></name><name><surname>Ling</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Antibacterial treatment of gastric ulcers associated with Helicobacter pylori</article-title><source> New Engl J Med</source><year>1995</year><volume>332</volume><fpage>139</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">7800005</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>JE</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Darboe</surname><given-names>MK</given-names></name><name><surname>Dale</surname><given-names>A</given-names></name><name><surname>Weaver</surname><given-names>LT</given-names></name></person-group><article-title>Isolation of Helicobacter pylori from human faeces</article-title><source> Lancet</source><year>1992</year><volume>340</volume><fpage>1194</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1359263</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokudome</surname><given-names>S</given-names></name><name><surname>Ghadimi</surname><given-names>R</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Helicobacter pylori infection appears the prime risk factor for stomach cancer</article-title><source> Int J Cancr</source><year>2006</year><month>12</month><day>15</day><volume>119</volume><issue>12</issue><fpage>2991</fpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotuneh</surname><given-names>N</given-names></name><name><surname>Hosseini</surname><given-names>SR</given-names></name><name><surname>Shokri-Shirvani</surname><given-names>J</given-names></name><name><surname>Bijani</surname><given-names>A</given-names></name><name><surname>Ghadimi</surname><given-names>R</given-names></name></person-group><article-title>Helicobacter pylori infection and metabolic parameters: is there an association in elderly population?</article-title><source> Int J Prev Med</source><year>2014</year><volume>5</volume><fpage>1537</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">25709789</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Federico</surname><given-names>A</given-names></name><name><surname>Gravina</surname><given-names>AG</given-names></name><name><surname>Miranda</surname><given-names>A</given-names></name><name><surname>Loguercio</surname><given-names>C</given-names></name><name><surname>Romano</surname><given-names>M</given-names></name></person-group><article-title>Eradication of Helicobacter pylori infection: which regimen first</article-title><source> World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>665</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24574740</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ierardi</surname><given-names>E</given-names></name><name><surname>Giorgio</surname><given-names>F</given-names></name><name><surname>Losurdo</surname><given-names>G</given-names></name><name><surname>Di</surname><given-names>Leo A</given-names></name><name><surname>Principi</surname><given-names>M</given-names></name></person-group><article-title>How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?</article-title><source> World J Gastroenterol</source><year>2013</year><volume>19</volume><fpage>8168</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">24363506</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Wannmacher</surname><given-names>L</given-names></name></person-group><source>Review of the evidence for H. Pylori treatment regimens. 18th Expert Committee on the Selection and Use of Essential Medicines</source><year>2011</year><comment>Available at:<ext-link ext-link-type="uri" xlink:href="http://www.who.int/selection_medicines/committees/expert/18/ap">http://www.who.int/selection_medicines/committees/expert/18/ap</ext-link></comment></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De</surname><given-names>Francesco V</given-names></name><name><surname>Giorgio</surname><given-names>F</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Worldwide H pylori antibiotic resistance: a systematic review</article-title><source> J Gastrointestin Liver Dis</source><year>2010</year><volume>19</volume><fpage>409</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">21188333</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zendedel</surname><given-names>A</given-names></name><name><surname>Moradimoghadam</surname><given-names>F</given-names></name><name><surname>Almasi</surname><given-names>V</given-names></name><name><surname>Zivarifar</surname><given-names>H</given-names></name></person-group><article-title>Antibiotic resistance of Helicobacter pylori in Mashhad, Iran</article-title><source> J Pak Med Assoc</source><year>2013</year><volume>63</volume><fpage>336</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23914633</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>CS</given-names></name><name><surname>Armstrong</surname><given-names>JA</given-names></name><name><surname>Chilvers</surname><given-names>T</given-names></name><etal/></person-group><article-title>Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen nov as Helicobacter pylori comb nov and Helicobacter mustelae comb nov, Respectively</article-title><source> Int J Syst Evol Microbiol</source><year>1989</year><volume>39</volume><fpage>397405</fpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>F</given-names></name><name><surname>Forero</surname><given-names>JD</given-names></name><name><surname>Rey</surname><given-names>M</given-names></name></person-group><article-title>Ideal treatment for Helicobacter pylori: a systematic review</article-title><source> Rev Gastroenterol Mex</source><year>2014</year><volume>79</volume><fpage>28</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">24365458</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onyekwere</surname><given-names>CA</given-names></name><name><surname>Odiagah</surname><given-names>JN</given-names></name><name><surname>Igetei</surname><given-names>R</given-names></name><etal/></person-group><article-title>Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study</article-title><source> World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>3615</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24707145</pub-id></element-citation></ref></ref-list></back></article>